Upscaling and Risk Evaluation of the Synthesis of the 3,5-Diamino-1H-Pyrazole, Disperazol.

Pyrazoles / chemistry Pseudomonas aeruginosa / drug effects Anti-Bacterial Agents / pharmacology Biofilms / drug effects Humans Pseudomonas Infections / drug therapy Risk Assessment
Pseudomonas aeruginosa biofilm c-di-GMP dispersal dust analysis flow chemistry large-scale synthesis preclinical pyrazole safety

Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
19 Jun 2024
Historique:
received: 23 05 2024
revised: 10 06 2024
accepted: 14 06 2024
medline: 27 6 2024
pubmed: 27 6 2024
entrez: 27 6 2024
Statut: epublish

Résumé

This paper presents the work performed to transition a lab-scale synthesis (1 g) to a large-scale (400 g) synthesis of the 3-5-diamino-1H-Pyrazole Disperazol, a new pharmaceutical for treatment of antibiotic-resistant

Identifiants

DOI: 10.3390/ijms25126737 PMID: 38928443
pubmed: 38928443
pii: ijms25126737
doi: 10.3390/ijms25126737
pii:
doi:

Substances chimiques

Pyrazoles 0
Anti-Bacterial Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Sygeforsikring Danmark
ID : 2021-0300

Auteurs

Charlotte Uldahl Jansen (CU)

Department of Chemistry, Technical University of Denmark, DK-2800 Lyngby, Denmark.
ORCID: 0000-0002-1168-8002

Katja Egeskov Grier (KE)

Department of Chemistry, Technical University of Denmark, DK-2800 Lyngby, Denmark.
ORCID: 0000-0002-9854-1440

Jens Bo Andersen (JB)

Costerton Biofilm Center, Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, DK-2200 Copenhagen, Denmark.
ORCID: 0000-0003-1720-1581

Louise Dahl Hultqvist (LD)

Costerton Biofilm Center, Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, DK-2200 Copenhagen, Denmark.
ORCID: 0000-0003-0256-892X

Martin Nilsson (M)

Department of Odontology, University of Copenhagen, DK-2200 Copenhagen, Denmark.
ORCID: 0000-0001-6251-9842

Claus Moser (C)

Costerton Biofilm Center, Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, DK-2200 Copenhagen, Denmark.
Department of Clinical Microbiology, Copenhagen University Hospital, Rigshospitalet, DK-2100 Copenhagen, Denmark.

Michael Graz (M)

Costerton Biofilm Center, Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, DK-2200 Copenhagen, Denmark.

Tim Tolker-Nielsen (T)

Costerton Biofilm Center, Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, DK-2200 Copenhagen, Denmark.

Michael Givskov (M)

Costerton Biofilm Center, Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, DK-2200 Copenhagen, Denmark.

Katrine Qvortrup (K)

Department of Chemistry, Technical University of Denmark, DK-2800 Lyngby, Denmark.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Azoles › Pyrazoles › Upscaling and Risk Evaluation of the Synthesis...
questionsmedicales.fr › Bactéries › Proteobacteria › Gammaproteobacteria › Pseudomonadaceae › Pseudomonas › Pseudomonas aeruginosa › Upscaling and Risk Evaluation of the Synthesis...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Anti-infectieux › Antibactériens › Upscaling and Risk Evaluation of the Synthesis...
questionsmedicales.fr › Phénomènes microbiologiques › Biofilms › Upscaling and Risk Evaluation of the Synthesis...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Upscaling and Risk Evaluation of the Synthesis...
questionsmedicales.fr › Infection › Infections bactériennes et mycoses › Infections bactériennes › Infections bactériennes à Gram négatif › Infections à Pseudomonas › Upscaling and Risk Evaluation of the Synthesis...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Statistiques comme sujet › Probabilité › Risque › Appréciation des risques › Upscaling and Risk Evaluation of the Synthesis...